Morgan Stanley Age X Therapeutics, Inc. Transaction History

Morgan Stanley

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Aug 16, 2024	BUY	$0.33 - $0.74 $145 - $326	441 New	441 $0
Q2 2023 Aug 14, 2023	SELL	$0.45 - $0.89 $20 - $40	-45 Reduced 9.26%	441 $0
Q1 2023 May 15, 2023	BUY	$0.56 - $0.8 $22 - $32	41 Added 9.21%	486 $0
Q4 2022 Feb 14, 2023	BUY	$0.54 - $0.68 $78 - $98	145 Added 48.33%	445 $0
Q3 2022 Nov 14, 2022	SELL	$0.55 - $0.74 $30 - $40	-55 Reduced 15.49%	300 $0
Q2 2022 Oct 27, 2022	SELL	$0.57 - $1.0 $1,461 - $2,564	-2,564 Reduced 87.84%	355 $0
Q2 2022 Aug 15, 2022	SELL	$0.57 - $1.0 $1,461 - $2,564	-2,564 Reduced 87.84%	355 $0
Q1 2022 Oct 27, 2022	BUY	$0.65 - $1.2 $1,666 - $3,076	2,564 Added 722.25%	2,919 $3,000
Q1 2022 May 13, 2022	SELL	$0.65 - $1.2 $63 - $117	-98 Reduced 3.25%	2,919 $3,000
Q4 2021 Feb 14, 2022	SELL	$0.53 - $1.09 $78 - $162	-149 Reduced 4.71%	3,017 $3,000
Q3 2021 Nov 15, 2021	BUY	$0.93 - $1.54 $2,944 - $4,875	3,166 New	3,166 $3,000

Ticker AGE
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,945,100
Description
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-rel...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.